Tempus AI (TEM) Projected to Post Quarterly Earnings on Monday

Tempus AI (NASDAQ:TEM) is anticipated to issue its quarterly earnings data after the market closes on Monday, February 24th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $202.80 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Tempus AI Price Performance

TEM opened at $68.09 on Friday. Tempus AI has a 12-month low of $22.89 and a 12-month high of $91.45. The stock has a 50-day moving average price of $50.29 and a 200-day moving average price of $51.72. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Insider Activity at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 51,504 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the sale, the executive vice president now directly owns 246,085 shares in the company, valued at approximately $10,431,543.15. This trade represents a 17.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the sale, the insider now owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. This represents a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,583,467 shares of company stock valued at $130,542,311 in the last 90 days.

Wall Street Analysts Forecast Growth

TEM has been the subject of several analyst reports. William Blair cut Tempus AI from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and increased their price objective for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Wolfe Research assumed coverage on Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Finally, TD Cowen reissued a “buy” rating and issued a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.